BHVN vs. RARE, CBAY, PBH, AXSM, INSM, BHC, XENE, FOLD, ALKS, and IDYA
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Ultragenyx Pharmaceutical (RARE), CymaBay Therapeutics (CBAY), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Insmed (INSM), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), Amicus Therapeutics (FOLD), Alkermes (ALKS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
Biohaven has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -139.70%. Biohaven's return on equity of -103.50% beat Ultragenyx Pharmaceutical's return on equity.
Biohaven has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
Biohaven presently has a consensus target price of $52.00, indicating a potential upside of 23.34%. Ultragenyx Pharmaceutical has a consensus target price of $91.55, indicating a potential upside of 111.03%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Biohaven.
Ultragenyx Pharmaceutical received 432 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 77.09% of users gave Ultragenyx Pharmaceutical an outperform vote while only 65.31% of users gave Biohaven an outperform vote.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Biohaven has higher revenue and earnings than Ultragenyx Pharmaceutical. Biohaven is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Biohaven. MarketBeat recorded 16 mentions for Ultragenyx Pharmaceutical and 15 mentions for Biohaven. Biohaven's average media sentiment score of 0.66 beat Ultragenyx Pharmaceutical's score of 0.45 indicating that Biohaven is being referred to more favorably in the media.
Summary
Biohaven and Ultragenyx Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
